Relevant bibliographies by topics / Amyloid-PET

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Amyloid-PET'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Amyloid-PET.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Amyloid-PET"

1

Rhodius-Meester, Hanneke F. M., Ingrid S. van Maurik, Lyduine E. Collij, et al. "Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET." PLOS ONE 19, no. 5 (2024): e0303111. http://dx.doi.org/10.1371/journal.pone.0303111.

Full text
Abstract:
Background The use of amyloid-PET in dementia workup is upcoming. At the same time, amyloid-PET is costly and limitedly available. While the appropriate use criteria (AUC) aim for optimal use of amyloid-PET, their limited sensitivity hinders the translation to clinical practice. Therefore, there is a need for tools that guide selection of patients for whom amyloid-PET has the most clinical utility. We aimed to develop a computerized decision support approach to select patients for amyloid-PET. Methods We included 286 subjects (135 controls, 108 Alzheimer’s disease dementia, 33 frontotemporal l
APA, Harvard, Vancouver, ISO, and other styles
2

Tan, Meng-Shan, Yu-Xiang Yang, Hui-Fu Wang, et al. "PET Amyloid and Tau Status Are Differently Affected by Patient Features." Journal of Alzheimer's Disease 78, no. 3 (2020): 1129–36. http://dx.doi.org/10.3233/jad-200124.

Full text
Abstract:
Background: Amyloid-β (Aβ) plaques and tau neurofibrillary tangles are two neuropathological hallmarks of Alzheimer’s disease (AD), which both can be visualized in vivo using PET radiotracers, opening new opportunities to study disease mechanisms. Objective: Our study investigated 11 non-PET factors in 5 categories (including demographic, clinical, genetic, MRI, and cerebrospinal fluid (CSF) features) possibly affecting PET amyloid and tau status to explore the relationships between amyloid and tau pathology, and whether these features had a different association with amyloid and tau status. M
APA, Harvard, Vancouver, ISO, and other styles
3

Frey, K. A., and R. A. Koeppe. "PET Amyloid Analyses." Journal of Nuclear Medicine 57, no. 8 (2016): 1168–69. http://dx.doi.org/10.2967/jnumed.116.173989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chételat, Gaël, and Melissa E. Murray. "Amyloid PET scan." Neurology 89, no. 20 (2017): 2029–30. http://dx.doi.org/10.1212/wnl.0000000000004678.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kepe, Vladimir. "Amyloid PET Imaging." PET Clinics 8, no. 4 (2013): 431–45. http://dx.doi.org/10.1016/j.cpet.2013.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Høilund-Carlsen, Poul F., Abass Alavi, and Jorge R. Barrio. "PET/CT/MRI in Clinical Trials of Alzheimer’s Disease." Journal of Alzheimer's Disease 101, s1 (2024): S579—S601. http://dx.doi.org/10.3233/jad-240206.

Full text
Abstract:
With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer’s disease. With the emergence of amyloid-PET tracers, [11C]Pittsburgh Compound-B in 2004 and later [18F]florbetapir, [18F]florbetaben, and [18F]flumetamol, amyloid-PET has replaced FDG-PET in Alzheimer’s disease anti-amyloid clinical trial treatments to ensure “amyloid positivity” as an entry criterion, and to measure treatment-related decline in cerebral amyloid deposits. MRI has been used
APA, Harvard, Vancouver, ISO, and other styles
7

Raposo, Nicolas, and Joshua A. Sonnen. "Amyloid-PET in cerebral amyloid angiopathy." Neurology 89, no. 14 (2017): 1437–38. http://dx.doi.org/10.1212/wnl.0000000000004548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Perani, Daniela. "FDG-PET and amyloid-PET imaging." Current Opinion in Neurology 27, no. 4 (2014): 405–13. http://dx.doi.org/10.1097/wco.0000000000000109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sarkis, Rani A., Seth A. Gale, Hyun-Sik Yang, et al. "Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline." American Journal of Alzheimer's Disease & Other Dementias® 38 (January 2023): 153331752311600. http://dx.doi.org/10.1177/15333175231160005.

Full text
Abstract:
In older adults with cognitive decline and epilepsy, diagnosing the etiology of cognitive decline is challenging. We identified 6 subjects enrolled in the Imaging Dementia-Evidence of Amyloid Imaging Scanning (IDEAS) study and nonlesional epilepsy. Three cognitive neurologists reviewed each case to determine the likelihood of underlying Alzheimer’s disease (AD) pathology. Their impressions were compared to amyloid PET findings. In 3 cases the impression was concordant with PET findings. In 2 cases “possibly suggestive,” the PET reduced diagnostic uncertainty, with 1 having a PET without elevat
APA, Harvard, Vancouver, ISO, and other styles
10

Isadora, Lopes Alves, E. Collij Lyduine, Altomare Daniele, et al. "Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study." Alzheimer's & Dementia 16, no. 5 (2020): 750–58. https://doi.org/10.1002/alz.12069.

Full text
Abstract:
<strong>Abstract</strong> Introduction:&nbsp;The Amyloid Imaging to Prevent Alzheimer&#39;s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer&#39;s disease (AD). AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD-related progression as well as address methodological challenges in amyloid PET. Methods:&nbsp;AMYPAD PNHS is an open-label, prospective, multi-center, cohort study recruiting from multiple PCs. Around 2000 participants will unde
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Amyloid-PET"

1

PEIRA, ENRICO. "Advances and perspectives in amyloid PET quantitative interpretation." Doctoral thesis, Università degli studi di Genova, 2022. http://hdl.handle.net/11567/1081904.

Full text
Abstract:
Amyloid imaging refers to a diagnostic examination that allows for the in-vivo detection of amyloid aggregation, considered a pathological hallmark of Alzheimer's disease (AD). The technique of choice for amyloid imaging is PET with appropriate radioligands, which has become a key tool in the diagnosis and research framework of AD. Due to the non-straightforward relationship between the presentation of the disease and the underlying molecular pathology, the diagnosis based purely on the clinical manifestation is a non-trivial task. Therefore, a great interest has developed around the methodolo
APA, Harvard, Vancouver, ISO, and other styles
2

Heurling, Kerstin. "Characterization of [18F]flutemetamol binding properties : A β-amyloid PET imaging ligand". Doctoral thesis, Uppsala universitet, Radiologi, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-262019.

Full text
Abstract:
The criteria for diagnosing Alzheimer’s disease (AD) have recently been revised to include the use of biomarkers for the in vivo presence of β-amyloid, one of the neuropathological hallmarks of AD. Examples of such biomarkers are positron emission tomography (PET) β-amyloid specific ligands, including [18F]flutemetamol. The aim of this thesis was to characterize the binding properties of [18F]flutemetamol from a tracer kinetic perspective as well as by validating binding measures through comparison with tissue pathology assessments. The applicability of previously developed kinetic models of t
APA, Harvard, Vancouver, ISO, and other styles
3

CHINCARINI, ANDREA. "From clinics to methods and back: a tale of amyloid-PET quantification." Doctoral thesis, Università degli studi di Genova, 2018. http://hdl.handle.net/11567/929831.

Full text
Abstract:
The in-vivo assessment of cerebral amyloid load is taking a leading role in the early differential diagnosis of neurodegenerative diseases. With the hopefully near introduction of disease-modifying drugs, we expect a paradigm shift in the current diagnostic pathway with an unprecedented surge in the request of exams and detailed analysis.
APA, Harvard, Vancouver, ISO, and other styles
4

Blaske, Susann. "Weiterentwicklung und Testung einer Auswerte-Software zur Analyse von Beta-Amyloid Hirn-PET-Daten." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-214479.

Full text
Abstract:
Alzheimer-Demenz ist eine Erkrankung, die durch den demografischen Wandel immer mehr an Bedeutung gewinnt. Eine effektive und frühzeitige Diagnostik ist daher entschei-dend. Da die neuropsychiatrische Testung mit einer diagnostischen Unsicherheit von 10% bis 30% zu ungenau ist und auch erst bei Ausbruch der Symptomatik eine Alzheimer-Demenz diagnostiziert werden kann, wurde auf Parameter wie Beta-Amyloid zurückgegrif-fen. Beta-Amyloid stellt einen Hauptbestandteil der Alzheimer-Demenz Pathologie dar und ist bereits vor Ausbruch der Symptome nachweisbar. Da die visuelle Analyse, welche die Beta
APA, Harvard, Vancouver, ISO, and other styles
5

Nordeman, Patrik. "Development of Palladium-Promoted 11C/12C-Carbonylations and Radiosynthesis of Amyloid PET Ligands." Doctoral thesis, Uppsala universitet, Plattformen för preklinisk PET, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-213863.

Full text
Abstract:
In the first part of this thesis, palladium(0)-catalyzed and -mediated carbonylations are discussed. Paper I describes a new method for the safe, efficient use of a solid carbon monoxide source in the synthesis of primary and secondary benzamides. In total, 35 benzamides were synthesized from aryl iodides (20 examples, 69-97% yield) and aryl bromides (15 examples, 32-93% yield). Reduction-prone groups were used successfully in the reactions. In paper II, the same protocol was adopted for the palladium(0)-catalyzed synthesis of N-cyanobenzamides from aryl iodides/bromides, carbon monoxide and c
APA, Harvard, Vancouver, ISO, and other styles
6

Salvadó, Blasco Gemma. "Detection of early cerebral amyloid-β deposition by PET imaging and its downstream effect". Doctoral thesis, Universitat de Barcelona, 2021. http://hdl.handle.net/10803/672375.

Full text
Abstract:
Alzheimer's disease (AD) is the leading cause of dementia worldwide. This disease, however, starts decades before any clinical symptom appears with the accumulation in the brain of aggregates of two main proteins: amyloid-β (Aβ) and tau. In recent years, the appearance of in vivo biomarkers capable to track biological changes has boosted the research interest to earlier phases of the disease. With these concepts in mind, the general objective of this thesis was to investigate Aβ deposition and its downstream effects in the earliest stages of the Alzheimer's continuum. To this aim, the four stu
APA, Harvard, Vancouver, ISO, and other styles
7

Bensaïdane, Mohamed Réda. "Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers." Master's thesis, Université Laval, 2016. http://hdl.handle.net/20.500.11794/27113.

Full text
Abstract:
La maladie d'Alzheimer (MA) se caractérise pathologiquement par l'accumulation de plaques amyloïde dans le cerveau. La tomographie par émission de positrons (TEP) permet d'imager les plaques amyloïde in vivo. Le but de ce projet est d’évaluer le rôle de la TEP amyloïde dans le processus diagnostique de la MA dans des cas de démences atypiques. Le deuxième but de ce projet est de déterminer l'impact de la révélation d’un diagnostic plus certain chez les proches aidants. 28 patients sans diagnostic malgré une investigation exhaustive ont été sélectionnées et imagées avec le traceur amyloïde 18F-
APA, Harvard, Vancouver, ISO, and other styles
8

Lilamand, Matthieu. "Apports des biomarquers amyloïdes dans la caractérisation de la plainte mnésique du sujet âgé." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS342.

Full text
Abstract:
Les biomarqueurs de la maladie d’Alzheimer (MA) permettraient d’identifier les processus pathologiques de la maladie plusieurs années avant l’apparition des premiers signes cliniques. Ainsi, la tomographie par émission de positons (TEP) reposant sur les radio-traceurs liant les plaques amyloïdes, a ouvert de nouvelles perspectives en matière d’identification précoce de la maladie, in vivo, très en amont des premiers symptômes. Cependant, l’utilisation de ces biomarqueurs est restée limitée à de faibles effectifs de sujets, rarement suivis au-delà de quelques mois et le coût important de ces ou
APA, Harvard, Vancouver, ISO, and other styles
9

Engler, Henry. "PET and the Multitracer Concept: An Approach to Neuroimaging Pathology." Doctoral thesis, Uppsala University, Department of Medical Sciences, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8687.

Full text
Abstract:
<p>Patients suffering from different forms of neurodegenerative diseases, such as: Creutzfeldt Jacob Disease (CJD), Alzheimer disease (AD), mild cognitive impairment (MCI), frontotemporal dementia and Parkinson’s disease (PD) were examined with Positron Emission Tomography (PET) and the combination of different radiotracers: <sup>15</sup>O-water, N-[<sup>11</sup>C-methyl]-L-deuterodeprenyl (DED), [<sup>18</sup>F] 2-fluorodeoxyglucose: (FDG), N-methyl-[<sup>11</sup>C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole (PIB) and L-[<sup>11</sup>C]-3,4-dihydroxiphenyl-alanine (DOPA). The radiotracers
APA, Harvard, Vancouver, ISO, and other styles
10

Niu, Zheng [Verfasser], Bernd [Akademischer Betreuer] Reif, Bernd [Gutachter] Reif та Aphrodite [Gutachter] Kapurniotu. "NMR Studies to Characterize Amyloid Inhibitors and Aβ-PET Tracer Complexes / Zheng Niu ; Gutachter: Bernd Reif, Aphrodite Kapurniotu ; Betreuer: Bernd Reif". München : Universitätsbibliothek der TU München, 2019. http://d-nb.info/119244180X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Amyloid-PET"

1

Rafii, Michael S. Alzheimer’s Disease. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0016.

Full text
Abstract:
Alzheimer’s disease (AD) is the most common cause of dementia worldwide, and is characterized by a protracted asymptomatic phase estimated to begin approximately 15 to 20 years. Clinically, AD initially manifests itself by progressive memory impairment, specifically, a loss of episodic memory function characterized by impaired free recall that does not improve with cueing. This is followed by a gradual decline in other cognitive domains leading to functional dependency, which essentially defines the dementia phase of the illness and has been the cornerstone of diagnostic criteria. About 50% of
APA, Harvard, Vancouver, ISO, and other styles
2

Rosenberg, Paul B. What are the First Signs and Symptoms of Dementia? Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199959549.003.0003.

Full text
Abstract:
Mild cognitive impairment (MCI) is a syndrome where persons have mild cognitive complaints and deficits on exam but are still functioning well in their daily lives. Persons with MCI are at markedly increased risk of developing dementia in the near-term and thus are an important target for preventive interventions. In the office it is crucial to take a careful history and to have an informant (usually a family member). Prodromal Alzheimer’s disease is typified by problems in short-term recall likely due to hippocampal dysfunction, and depression and anxiety are relatively common. Brief cognitiv
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Amyloid-PET"

1

Drzezga, Alexander, and Kathrin Giehl. "Amyloid PET Imaging." In Molecular Imaging of Neurodegenerative Disorders. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-35098-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Matsuda, Hiroshi, and Tensho Yamao. "Amyloid PET Imaging and Quantification of Amyloid Deposition." In Neuromethods. Springer US, 2025. https://doi.org/10.1007/978-1-0716-4494-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

D’Amico, Francesca, Luca Sofia, Matteo Bauckneht, and Silvia Morbelli. "Amyloid PET Imaging: Standard Procedures and Semiquantification." In Biomarkers for Alzheimer’s Disease Drug Development. Springer US, 2024. http://dx.doi.org/10.1007/978-1-0716-3774-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tolboom, Nelleke, Rik Ossenkoppele, and Bart N. van Berckel. "Amyloid-β PET Imaging in Aging and Dementia." In PET/CT in Brain Disorders. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-01523-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nordberg, Agneta. "PET Tracers for Beta-Amyloid and Other Proteinopathies." In PET and SPECT of Neurobiological Systems. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-42014-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Arbizu, Javier, and Gloria Martí-Andres. "Case 11: Corticobasal Syndrome: [18F]FDG and Amyloid PET." In Clinical Nuclear Medicine in Neurology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83598-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Okamura, Nobuyuki, and Ryuichi Harada. "PET Imaging of Amyloid and Tau in Alzheimer’s Disease." In Aging Mechanisms II. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7977-3_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Arbizu, Javier, and Juan Fernando Bastidas. "Case 2: Alzheimer’s Disease—[18F]FDG, Tau, and Amyloid PET." In Clinical Nuclear Medicine in Neurology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83598-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Blennow, Kaj, and Henrik Zetterberg. "The Neurochemistry of Alzheimer’s Disease: One of the Most Common Causes of Reduced Capability in the Adult Population." In International Perspectives on Aging. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-78063-0_7.

Full text
Abstract:
AbstractAlzheimer’s disease (AD) is the most common form of dementia and is characterised by the triad of amyloid plaques, tau pathology and neurodegeneration. Except for a strong association with the susceptibility gene, specifically the apolipoprotein E (APOE) ε4 allele, the pathogenesis of the most common age-related sporadic form of AD is largely unknown. However, several genetic and environmental risk factors have been proposed. A potential problem is that most population-based studies on AD risk-profiling have not used biomarkers reflecting amyloid and tau pathology to classify patients
APA, Harvard, Vancouver, ISO, and other styles
10

Morbelli, Silvia, and Matteo Bauckneht. "Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers." In Biomarkers for Alzheimer’s Disease Drug Development. Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7704-8_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Amyloid-PET"

1

Seol, Y. J., H. B. Yoo, E. J. Yoon, Y. K. Kim, and J. S. Lee. "Brain MRI Synthesis from Amyloid PET/CT via Enhanced Denoising Diffusion Probabilistic Model." In 2024 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD). IEEE, 2024. http://dx.doi.org/10.1109/nss/mic/rtsd57108.2024.10655396.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Studart-Neto, Adalberto, Artur Coutinho, Camila Carneiro, et al. "ACCURACY OF FIGURE MEMORY TEST OF THE BRIEF COGNITIVE SCREENING BATTERY TO PREDICT AMYLOID STATUS IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda011.

Full text
Abstract:
Background: Some older adults with subjective decline (SCD) had a positive amyloid biomarker indicating a preclinical stage of Alzheimer’s disease. Objectives: To assess the accuracy of Delayed Recall of Figure Memory Test (DR-FMT) of Brief Cognitive Screening Battery to predict amyloid status in SCD older adults. Objective: To assess the accuracy of Delayed Recall of Figure Memory Test (DR-FMT) of Brief Cognitive Screening Battery to predict amyloid status in SCD older adults. Methods: The sample consisted of 45 older adults classified as SCD and 25 as controls without complaints (mean age of
APA, Harvard, Vancouver, ISO, and other styles
3

Fu, Yu, Le Xue, Yi Liao, et al. "Cross-Modality Generation of Amyloid PET from FDG PET for Alzheimer’s Disease Diagnosis." In 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669287.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zukotvnski, Katherine, Vincent C. Gaudet, Phillip Kuo, et al. "Non-Binary Approaches for Classification of Amyloid Brain PET." In 2019 IEEE 49th International Symposium on Multiple-Valued Logic (ISMVL). IEEE, 2019. http://dx.doi.org/10.1109/ismvl.2019.00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Parmera, Jacy, Artur Coutinho, Isabel Almeida, et al. "CORTICOBASAL SYNDROME: A PROSPECTIVE STUDY OF CLINICAL PROFILES AND IMAGING BIOMARKERS." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda010.

Full text
Abstract:
Background: Corticobasal syndrome (CBS) is neurodegenerative disorder related to multiple underlying pathologies. Objective: To investigated if dividual FDG-PET patterns could distinguish CBS due to Alzheimer’s disease (AD) from other pathologies based on [11C]Pittsburgh Compound-B (PIB)-PET. Methods: Forty-five patients with probable CBS were prospectively evaluated. They underwent FDG-PET and were divided into groups: related to AD (CBS FDG-AD) or non-AD (CBS FDG-nonAD). Thirty patients underwent PIB-PET on a PET-MRI to assess their amyloid status. FDG and PIB-PET were classified individuall
APA, Harvard, Vancouver, ISO, and other styles
6

Schürer, M., KT Chen, T. Jochimsen, et al. "Einfluss künstlicher Intelligenz auf beta-Amyloid(Aß)-PET/MRT-Untersuchungen." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Silva, Maria Rosa Alves da, Rodrigo Twardowski Scherer, Fabricio Nery Garrafiel, and Lucas Porcello Schilling. "Quantification of pet amyloid [18] florbetaben using the centiloid scale." In Reunião de Pesquisadores em Doença de Alzheimer e Desordens Relacionadas. Academia Brasileira de Neurologia, 2024. http://dx.doi.org/10.22491/19805764/067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hooshyar Yousefi, B., T. Grimmer, K. Shi, et al. "FIBT may expand PET for ß-amyloid imaging in neurodegenerative diseases." In NuklearMedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1683664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smith, Anne M., Dawn Matthews, and Randolph Andrews. "Assessment of PET Amyloid Quantification Differences by Varying the Reconstruction Protocol." In 2017 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC). IEEE, 2017. http://dx.doi.org/10.1109/nssmic.2017.8532760.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Souza, Giordana S., Samara O. Pinto та Ana Maria Marques da Silva. "Evaluation of MR-less in brain amyloid-β PET Centiloid quantification". У Biomedical Applications in Molecular, Structural, and Functional Imaging, редактори Barjor S. Gimi та Andrzej Krol. SPIE, 2022. http://dx.doi.org/10.1117/12.2611904.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Amyloid-PET"

1

Mathis, CA. Development of [F-18]-Labeled Amyloid Imaging Agents for PET. Office of Scientific and Technical Information (OSTI), 2007. http://dx.doi.org/10.2172/903085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Amyloid-PET' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography